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Abstract
Background: Species-specific point-of-care tests (POCT) permit a rapid analysis of canine C-reactive protein (CRP),
enabling veterinarians to include CRP in clinical decisions. Aim of the study was to evaluate a novel POCT for canine CRP
(Point Strip™ Canine CRP Assay) run on a small in-house-analyzer (Point Reader™ V) using lithium heparin plasma and to
compare assay performance to an already established canine CRP assay (Gentian Canine CRP Immunoassay) run on two
different bench top analyzers serving as reference methods (ABX Pentra 400, AU 5800).
Linearity was assessed by stepwise dilution of plasma samples with high CRP concentrations. Limit of quantification (LoQ)
was determined by repeated measurements of samples with low CRP concentrations. Coefficient of variation (CV) at low
(10–50 mg/l), moderate (50–100 mg/l), and high (100–200 mg/l) CRP concentrations was investigated as well as possible
interferences. Method comparison study was performed using 45 samples of healthy and diseased dogs. Quality criteria
were fulfilled if the total observed error (TEobs = 2CV% + bias%) was below the minimal total allowable error of 44.4% (TE
min). Additionally, a reference range (n = 60 healthy dogs) was established.
Results: Linearity was present at CRP concentrations of 10–132 mg/l (≙ 361 mg/l CRP with reference method) with a
LoQ set at 10 mg/l. At moderate to high CRP concentrations, intra- and inter-assay CVs were ≤ 8% and ≤ 11%
respectively, while CVs ≤ 22% and ≤ 28% were present at low concentrations. No interferences were observed at
concentrations of 4 g/l hemoglobin, 800 mg/l bilirubin and 8 g/l triglycerides. Method comparison study demonstrated
an excellent correlation with both reference methods (r = 0.98 for ABX Pentra 400; 0.99 for AU 5800), though revealing
a proportional bias of 19.7% (ABX Pentra 400) and 10.7% (AU 5800) respectively. TEobs was 26.7–31.9% and 16.7–21.9%
and thus < TEmin. Healthy dogs presented with CRP values ≤11.9 mg/l.
Conclusions: The POCT precisely detects canine CRP at clinically relevant moderate and high CRP concentrations.
The assay correlates well with both reference methods. Due to the bias, however, follow-up examinations should be
performed with the same assay and analyzer.
Keywords: Acute phase protein, C-reactive protein, Canine, Method validation, Point-of-care assay, Point-of-care
analyzer, Total allowable error, Bias, Heparin plasma, Interference
Background
C-reactive protein (CRP) is an important major acute
phase protein (APP) in the dog. APPs are an integral
part of innate immune response and change their serum
concentration in adaption to a systemic inflammation
[1–4]. Contrary to classic markers of inflammation as
the white blood cell count, APPs react more rapidly and
with a shorter half-life period [1, 5]. According to their
kinetics, APPs are classified as slowly and mildly react-
ing minor and moderate APP or as rapidly reacting
major APP, which increase 100- to 1000-fold within
24-48 h and decrease rapidly after disappearance of the
inflammatory stimulus [3]. These sensitive markers of
inflammation have been shown to increase in response
to infectious diseases [6–9], immune mediated diseases
[10–12], neoplasia [10, 13, 14], and surgery [15].
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However, in the past, the measurement of canine CRP
was hampered by the lack of a species-specific test avail-
able for veterinary practices and clinics.
Different assays for canine CRP were developed or
adopted from human medicine and there was a shift
from heterologous to homologous immunoassays which
provide more reliable results [16–19]. Recently, a
commercially available canine CRP assay was intro-
duced on the market that is designed to be run on au-
tomated large bench top analyzers. First evaluations
demonstrated its capability to detect canine CRP with a
high precision and accuracy [20]. However, patients
with severe inflammatory processes are often presented
as emergency cases, so that a rapid measurement of
CRP is desirable.
In human medicine, near-patient assays are available
in order to fulfill this aim [21, 22].
Few canine species-specific CRP in-house tests have
been evaluated in the past. The first point-of-care tests
(POCT) were only semiquantitative, providing results of
limited benefit and leading sometimes to falsely positive
results [23–26]. Later, quantitative assays became available
[27, 28]. Method comparison studies have often been per-
formed with a manual ELISA serving as reference method,
which, however, is impaired by a lack of precision.
Recently, a novel quantitative homologous bedside
canine CRP assay (Point Strip™ Canine CRP Kit, USHIO
Europe B.V., BC Oude Meer, The Netherlands) run on
the in-house analyzer Point Reader™ V, USHIO Europe
B.V., BC Oude Meer, The Netherlands became
commercially available. The Point Strip™ Canine CRP
assay for the Point Reader™ V is a test strip based col-
loidal gold immunochromatographic assay with
species-specific rabbit anti-dog-CRP antibodies, which
form complexes with canine CRP. These complexes
migrate by capillary action through the membrane and
are bound to the test line. Remaining non-bound
antibodies are bound to the control line. The same
test principle was used in a semiquantitative assay
before [25].
Thus, it was the aim of our study to evaluate the ease
of use and the test performance including linearity and
lower limit of quantification (LoQ), precision and total
observed error (TEobs) as well as interferences with bili-
rubin, hemoglobin and lipid of the canine species-
specific in-house CRP assay run on the Point Reader™ V.
In a method comparison study, the assay was compared
with a canine CRP test which has been validated before
[20, 29] run on two automated analyzers serving as ref-
erence methods. Furthermore, the reference range was
evaluated. The hypothesis was that the investigated
point-of-care analyzer is easy-to-use and that the results
obtained with the POCT correlate well with the refer-
ence bench top analyzers.
Methods
The prospective study was performed between September
2016 and July 2017.
Measurement of CRP
Analyses were performed on surplus lithium heparin
plasma submitted for CRP analysis to the Department of
Veterinary Clinical Sciences, Clinical Pathology and
Clinical Pathophysiology, Justus-Liebig-University
Giessen, Germany. Samples were analyzed immediately
(< 1 h after blood collection) with the Gentian Canine
CRP Immunoassay (Gentian AS, Moss, Norway), which
served as the reference assay, on the ABX Pentra 400
clinical chemistry analyzer (ABX Horiba, Montpellier,
France) as described before [29]. The initially performed
CRP analysis as part of routine diagnostics was used to
assign the sample to one of the three concentration
ranges: CRP 10–50 mg/l (low); 50–100 mg/l (medium),
and 100–200 mg/l (high). The application of reagents
and samples and the measurements on the in-house
analyzer as well as on the large bench top analyzers were
done by a single trained person for each analyzer
according to the manufacturer’s instructions. In the
method comparison study, the Point Strip™ Canine CRP
POCT run on the Point Reader™ V (test and analyzer
combination is subsequently just named “Point Reader™
V” or “POCT”) was compared to the reference assay run
on two bench top analyzers (ABX Pentra 400, ABX
Horiba, Montpellier, France and AU 5800, Beckman
Coulter, Krefeld, Germany).
Method validation
Linearity and recovery Linearity was evaluated by man-
ual stepwise dilution of two canine lithium heparin
plasma samples with markedly increased CRP concen-
tration of ~ 245 and 360 mg/l determined on the ABX
Pentra 400 analyzer which was used as a reference
method. Serial dilution resulted in specimens with 1.0,
0.8, 0.6, 0.4, 0.2, 0.1, 0.05, and 0.025 of the original CRP
concentration. All diluted aliquots were analyzed in trip-
licates in a single run. For all dilution steps % recovery
rate was evaluated by comparison of expected and mea-
sured results. Furthermore, the dilution series was used
for calculation of the recovery rate. The experiment was
conducted twice to verify the measurements.
Precision and lower limit of quantification Precision
was assessed at three CRP concentration levels, i.e. low,
moderate and high CRP concentrations. Intra- and inter-
assay coefficients of variation (CVs) for the POCT were
calculated from replicate measurements performed with
samples of eight dogs each, whereby four samples of the
lowest concentration range and two samples each of the
moderate and high CRP concentration range were
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included. For assessment of intra-assay CV, ten replicate
measurements were performed (n = 8 dogs). Inter-assay
CV was calculated from single measurements performed
on seven consecutive days (n = 8 dogs).
For assessment of LoQ, three lithium heparin plasma
samples with CRP concentrations close to zero (20 mg/l,
10 mg/l, 0.8 mg/l) were assessed 20 times in a single run
without recalibration as previously recommended [30].
Interferences In order to investigate possible interfer-
ences, aliquots of a canine lithium heparin plasma sam-
ple with a medium concentration of ~ 50 mg/l CRP as
assessed on the ABX Pentra 400 were spiked with
800 mg/l bilirubin (Bilirubin - ≥98%, powder, Sigma-
Aldrich Co. LLC., St. Louis, Missouri, USA), 4 g/l
hemoglobin (hemoglobin from bovine blood, lyophilized
powder, Sigma-Aldrich Co. LLC., St. Louis, Missouri,
USA) or 8 g/l 20% soy bean emulsion (Intralipid 20%,
Fresenius Kabi Canada, Ontario, Canada). For assess-
ment of the effect of hyperbilirubinemia, 20 mg bilirubin
was dissolved in 1 ml of 0.1 M NaOH obtaining a stock
solution of 20 g/l. Subsequently, 5 μl of the product was
added to 120 μl of a non-spiked lithium heparin plasma
sample to achieve a bilirubin level of 800 mg/l.
A stock solution containing 100 g/l hemoglobin was
prepared by diluting 30 mg lyophilized bovine hemoglobin
in 0.3 ml 0.09% NaCl. Then, 5 μl of the solution was
added to 120 μl non-spiked lithium heparin plasma sam-
ple resulting in a hemoglobin concentration of 4 g/l.
To evaluate the possible impact of lipemia on results, 5 μl
of Intralipid was added to 120 μl of non-spiked lithium
heparin plasma sample so that a concentration of soya bean
oil of 8 g/l was obtained. Analysis was performed in tripli-
cates in random order. The spiked samples were investi-
gated in comparison to lithium heparin plasma aliquots
spiked with equal volumes of either 100 mM NaOH (in
case of bilirubin), 0.09% NaCl (hemoglobin) or pure
double-distilled water (in case of Intralipid).
Method comparison
In the method comparison study, the POCT was com-
pared to a canine CRP assay run on two bench top ana-
lyzers (ABX Pentra 400; AU 5800). First, routine
biochemical analysis including measurement of CRP was
performed with the ABX Pentra 400 clinical chemistry
analyzer of samples submitted to the Department of
Veterinary Clinical Sciences, Clinical Pathology and
Clinical Pathophysiology, Justus-Liebig-University
Giessen, Germany. Specimens were included in the
study if it was expected that sufficient residual sample
volume was available to be re-analyzed with the POCT
and the two bench top analyzers ABX Pentra 400 and
AU 5800, respectively. The remainder lithium heparin
plasma was then divided in three aliquots and stored at
− 80 °C until analysis with the POCT and on the two
bench top analyzers. Sampling was performed until 15
specimens for each CRP concentration range (low, mod-
erate, high) were collected.
After finishing the period of sample acquisition and col-
lecting a total number of 45 lithium heparin plasma speci-
mens [31], two aliquots each were thawed at room
temperature and re-analyzed in the Department of
Veterinary Clinical Sciences, Clinical Pathology and Clin-
ical Pathophysiology with the POCT and ABX Pentra 400
analyzer. The corresponding third aliquot of each sample
was sent frozen to the commercial veterinary laboratory
SYNLAB Vet GmbH, Augsburg, Germany to be analyzed
on the AU 5800 analyzer. On both bench top analyzers,
the same commercially available immunoturbidimetric ca-
nine specific CRP test was performed.
For all three analyzers, measurements were performed
in duplicates to allow a direct comparison between the
analyzers by calculation of the total observed error
(TEobs) from intra-assay CV and %bias [31].
Establishment of reference intervals
For the reference interval study, lithium heparin plasma
samples of 60 healthy adult dogs (> 1 year) were
included. The dogs were presented at the Clinic for
Small Animals, Faculty of Veterinary Medicine, Justus-
Liebig-University, Giessen, Germany, as blood donors or
for routine radiologic examination to screen for heredi-
tary hip or elbow dysplasia. The dogs were classified as
healthy and included in the study based on an unre-
markable anamnesis and clinical examination.
Statistical analysis
Statistical software programs (MedCalc, software version
16.2.1; Ostend, Belgium and GraphPad Prism 6 Software,
GraphPad Software, Inc., La Jolla, USA) were used for
statistical assessment of the obtained data.
Method validation
Results for CV%, bias% and TEobs were compared to qual-
ity specifications derived from biologic variation published
previously in the Total allowable error (TE) guidelines of
the American Society of Veterinary Clinical Pathology
(ASVCP, Table 1) [32]. For the purpose of the current
Table 1 Quality specifications
Acceptance limits Quality parameters CV (%) Bias (%) TE (%)
- minimally acceptable 18.2 14.3 44.4
- desired 12.2 9.5 29.6
- optimal 6.1 4.8 14.8
Quality specifications are derived from biological variation as published in the
addendum of the Total allowable error guidelines of the American Society of
Veterinary Clinical Pathology [32]
Abbreviations: CV coefficient of variation, TE total allowable error
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study, numbers are rounded to one decimal place. Routine
descriptive statistics were applied to calculate arithmetic
means, standard deviations (SD), and CV. Normality was
assessed using the Shapiro-Wilk Test.
Linearity and recovery Linearity under dilution was in-
vestigated by visual inspection of the correlation of
observed CRP values plotted against a calculated (ex-
pected) CRP concentration. The difference between ac-
tual and theoretical CRP concentration was used to
assess recovery after dilution:
Recovery% ¼ measured concentration
expected concentration
 100
The quality goal for recovery after dilution was set at
the range of 80–120% as recommended previously for
validation of immunoassays [33, 34]. Linear and Deming
regression analysis were performed to assess the correl-
ation between expected and measured results.
Precision and lower limit of quantification Quality re-
quirements were fulfilled if the observed CV was < than
the desired CV (CVdes) for CRP (CVdes, 12.2%) or at
least < than the minimally acceptable CV (CVmin, 18.2%)
as reported previously [32].
Imprecision was computed based on mean and stand-
ard deviation (SD):
CV% ¼ SD
Mean
 100
Interferences The impact of possible interferences was
evaluated by comparing control samples “spiked” with
equal volumes of NaOH (instead of bilirubin), 0.09%
NaCl (instead of hemoglobin) or pure double-distilled
water (instead of Intralipid) as well as samples spiked
with the interfering substances (bilirubin, hemoglobin,
Intralipid) which were analyzed in triplicates.
The observed interference effect (dobs) was determined
as the %bias between the mean of the test and the con-
trol samples:
dobs% ¼ meantest−meancontrolmeancontrol  100
Bias between control and test sample (i.e., dobs %) was
considered acceptable according to the current literature
if it was below the allowable TE, i.e. 29.6% (TEdes) or
even below 14.8% (TEopt) for canine CRP [32, 35].
Method comparison
Statistical analysis included the calculation of CVs from
duplicate measurements for all three analyzers and con-
centration ranges. CV quality criteria were fulfilled if
CV < CVdes (12.2%) or at least CV < CVmin (18.2%) as
shown in Table 1 [32]. The means of the duplicate mea-
surements were used for all further statistical tests.
For method comparison, a Bland Altman analysis was
performed and both, %bias and absolute bias were calcu-
lated. Moreover, Passing Bablok analysis and calculation
of Spearman’s rank correlation coefficient were performed.
Correlations were considered “excellent” for Spearman’s
rho (rs) =0.93–0.99, “good” for rs = 0.80–0.92, “fair” for
rs = 0.59–0.79, and “poor” for rs < 0.59, respectively [36].
As demonstrated in Table 1, quality criteria for bias
were fulfilled if the mean observed %Biasobs < %Biasdes
(desired bias) or at least < %Biasmin (minimally accept-
able bias) [32].
A Shapiro Wilk test was used to verify the assumption
of normality. As non-normal distribution was present, a
Kruskal-Wallis test was performed to assess a potential
difference between median CRP measurements obtained
for each analyzer.
To more objectively judge results, TEobs was calculated
and compared with quality specifications published pre-
viously for the measurements of CRP, i.e. the desirable
total allowable error (TEdes) and the minimally accept-
able total error (TEmin) [32].
TEobs was calculated as published previously [27]:
TEobs = 2*CV% + bias%.
Quality requirements are fulfilled if TEobs < TEdes
(29.6%) or TEmin (44.4%) (Table 1) [32].
Establishment of reference intervals
As healthy dogs showed CRP values frequently (54/60
dogs) below the reported CRP concentration of the
point-of-care analyzer (< 5 mg/l), a calculation of a
definite reference interval was not possible.
Results
Method validation
Ease of use
The investigated point-of-care analyzer demonstrated to
be a user-friendly in-house analyzer which could be eas-
ily used after a short training period.
Dilution buffer and test stripes have to be brought up
from fridge to room temperature. Meanwhile, the
analyzer is booting up and the clinician can use the time
to centrifuge the blood sample to gain plasma (or
serum). Then, 10 μl of the sample is pipetted in the dilu-
tion bottle filled with an adequate amount of dilution
buffer and mixed 10 times. Afterwards, 100 μl of the di-
lution are applied on the test strip which is inserted in
the analyzer. Measurement starts automatically and a
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result is provided after 5–10 min of kinetic measure-
ment. Only if a new box of test stripes is opened, a cali-
bration stripe for this batch of test stripes has to be
inserted before measurement of a sample. All equipment
(dilution bottle, test stripe) is for single use. One meas-
urement including all preparations and waiting time for
the reagents to acclimatize takes about 20–25 min.
Expiration period of the test kit with 30 strips is
6 months at fridge temperature.
Linearity and recovery
The results of the two linearity experiments are shown
in Fig. 1 a) and b) as well as in Table 2 a) and b).
As displayed in Fig. 1 a) and b), there was an excellent
correlation between expected and measured results. For
the POCT, linearity was given up to the highest CRP
concentrations assessed of a mean of 123 and 130 mg/l.
Comparison between expected and measured results
revealed a marked proportional Biasobs ranging between
6.8 and 63.4% (Table 2). The Biasobs and subsequently
the TEobs were exceeding quality requirements for sam-
ples with a dilution factor ≥ 0.025 and 0.1 respectively.
Precision and lower limit of quantification
Inter- and intra- assay CVs calculated from replicate
measurements are shown in Table 3. As seen in the
table, intra- assay CV was ≤8% in most cases and inter-
assay CV ≤ 11%, respectively and thus < CVdes of 12.2%.
The only exception were samples with a relatively low
CRP concentration < 25 mg/L, where higher intra- and
inter-assay CVs of 13.2–21.8% and 27.2% were obtained.
In the LoQ study (Table 4), the lowest sample with a
CRP concentration of 0.8 mg/l was correctly reported as
< 5 mg/l, therefore the calculation of a CV was not pos-
sible. The CVs of 20 replicate measurements of samples
with CRP concentrations of 10 mg/l and 20 mg/l re-
spectively fulfilled the quality goal of CVobs < CVdes of
12.2% (6.2%, 11%). The LoQ was set at 10 mg/l as this
was the lowest CRP concentration evaluated that
achieved the quality criteria.
Interferences
No interference was detectable up to a concentration of
800 mg/l bilirubin, 4 g/l hemoglobin and 8 g/l soy bean
oil (Table 5).
Mean %Biasobs between control and spiked test sam-
ples was < TEopt and thus fulfilling quality requirements.
Method comparison
Overall, 45 samples were included for the comparison
between the POCT and the Gentian canine CRP im-
munoassay run on the ABX Pentra 400 analyzer. For the
comparison between the POCT and AU 5800, 2/45 sam-
ples were excluded due to insufficient sample volume.
Intra-assay CVs obtained for duplicate CRP measure-
ments for the three evaluated analyzers are shown in
Table 6. As seen in the table, median CVs < 1% and 2%
were obtained for the automated bench top analyzers
ABX Pentra 400 and AU 5800 with a range of 0%–3.2%
and 0.3–5.6% respectively.
For the POCT, median intra-assay CVs were < 6%,
however, there was a broad range especially in the low
concentration range (0% to 38.9%).
Results of the method comparison study are shown in
Fig. 2. There was an excellent correlation between CRP
measurements obtained with the three analyzers (rs ran-
ging between 0.98 and 0.99, Fig. 2 A1–3).
Passing-Bablok regression analysis revealed a correl-
ation of rs = 0.98 between the data obtained with POCT
and measurements of the ABX Pentra 400 with the
regression eq. Y = − 0.12 + 0.82×. Regression analysis be-
tween POCT and AU 5800 revealed a Spearman’s rank
correlation coefficient of rs = 0.99 and the regression eq.
Y = − 0.52 + 0.91×. In the additional correlation analysis
between ABX Pentra 400 and AU 5800 using the same
CRP assay, a Spearman’s rank correlation coefficient of
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Fig. 1 Linearity of two diluted lithium heparin plasma samples with high CRP concentrations. a Linearity under dilution for measurement of a
canine serum sample originally containing 244.8 mg/l CRP as assessed with the Pentra 400 bench top analyzer. b Linearity under dilution for
measurement of a canine serum sample originally containing 361.3 mg/l CRP as assessed with the Pentra 400 bench top analyzer. A serial
dilution was performed in both cases to achieve 8 different CRP concentrations, i.e, 1.0, 0.8, 0.6, 0.4, 0.2, 0.1, 0.05, 0.025 parts of the
original concentration
Hindenberg et al. BMC Veterinary Research  (2018) 14:99 Page 5 of 12
rs = 0.99 and the regression eq. Y = 0.57 + 0.90× was
obtained.
As demonstrated in Fig. 2 B1–2, Bland Altman ana-
lysis revealed a proportional Biasobs of 10.7% and 19.7%
between CRP measurement obtained with the POCT
and the two automated bench top analyzers AU 5800
and ABX Pentra 400, respectively. All three analyzers
revealed a growing absolute bias with increasing CRP
concentration (Fig. 2 C1–3). Especially the POCT and
ABX Pentra 400 analyzer disagreed considerably (Fig. 2
B1–2, C1–2) exceeding the %Biasmin of 14.3%. Biasobs
was lower between the POCT and the AU 5800 analyzer
being < %Biasmin. Interestingly, even between both bench
top analyzers using the same CRP assay, a mean Biasobs
of 9.2% was seen (Fig. 2 B3), which, however, was still <
both %Biasdes and %Biasmin of 9.5% and 14.3%, respect-
ively. As shown in Fig. 3, there was a significant differ-
ence between mean CRP measurements obtained with
all analyzers, whereby highest CRP measurements were
Table 2 Linearity and recovery
Dilution Factor Expected concentration [mg/l] Mean measured
concentration [mg/l]
Recovery [%] Biasobs [%] %Biasobs < TEdes (29.6%) %Biasobs < TEmin (44.4%)
A
0.025 6.1 6.5 106.8 6.8 Yes Yes
0.05 12.2 11.9 97.0 3.1 Yes Yes
0.1 24.5 19.8 81.0 19.0 Yes Yes
0.2 49.0 36.5 74.6 25.5 Yes Yes
0.4 97.9 59.8 61.0 39.0 No Yes
0.6 146.9 79.8 54.3 45.7 No No
0.8 195.8 88.0 44.9 55.1 No No
1 244.8 122.3 50.0 50.1 No No
B
0.025 9.0 6.2 68.7 31.3 No No
0.05 18.1 12.3 68.3 31.7 No No
0.1 36.1 20.4 56.6 43.4 No No
0.2 72.2 36.7 50.8 49.2 No No
0.4 144.4 72.5 50.2 49.8 No No
0.6 216.6 85.8 39.6 60.4 No No
0.8 288.8 112.6 39.0 61.0 No No
1 361.3 132.4 36.7 63.4 No No
Linearity and recovery rates of CRP measurements performed with a canine serum sample containing A) 244.8 mg/l or B) 361.3 mg/l CRP respectively as determined on
the ABX Pentra 400 analyzer
Quality parameters exceeding the quality criteria reported previously [32, 36], are marked in bold letters
Abbreviations: Biasobs observed bias, TE total allowable error, TEdes desirable TE, TEmin minimally acceptable TE
Table 3 Intra- and inter-assay CVs obtained from replicate CRP
measurements with the POCT
Three CRP
concentration
ranges / analyzer
Doga Intra-assay CV
(n = 10 replicates)
Inter-assay CV
(n = 7 replicates)
Mean
(mg/l)
SD
(mg/l)
CV
(%)
Mean
(mg/l)
SD
(mg/l)
CV
(%)
≥ 10 - < 50 mg/l 1 21.3 4.7 21.8 23.2 6.3 27.2
2 43.1 2.3 5.4 32.3 2.0 6.2
3 23.1 3.7 16.3 15.4 0.8 5.0
4 29.9 4.0 13.2 32.2 2.8 8.8
≥ 50 - < 100 mg/l 5 55.7 3.0 5.5 71.0 7.6 10.7
6 79.8 4.7 5.9 74.4 5.5 7.3
≥ 100 - < 200 mg/l 7 113.9 7.4 6.5 102.4 7.2 7.0
8 113.9 9.1 8.0 110.5 11.1 10.0
aSamples from different dogs were used for assessment of intra- and inter- assay CV
CV > CVdes (i.e., 12.2%) and CV > CVmin (i.e., 18.2%) is shown in bold letters
Abbreviations: SD standard deviation, CV coefficient of variation, CVdes desirable
CV, CVmin minimally acceptable CV
Table 4 Determination of the lower limit of quantification
Three low CRP
concentrations
Dog Intra-assay CV
(n = 20 replicates)
Mean
(mg/L)
SD
(mg/L)
CV
(%)
% CV < CVdes
(12.2%)
< 1 mg/l 1 < 5* n.d. n.d. n.d.
~ 10 mg/L 2 11.5 0.7 6.2 Yes
~ 20 mg/l 3 16.8 1.8 11.0 Yes
Intra-assay CVs for the CRP analysis obtained from replicate measurements at
low CRP values with the POCT
*values < 5 mg/l are generally reported as “< 5 mg/l”, therefore no further
calculations were possible
Abbreviations: SD standard deviation, CV coefficient of variation, CVdes desirable
CV, n.d. not done
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obtained with the ABX Pentra 400 analyzer and lowest
results with the POCT. Median (minimum to
maximum) values obtained were 76.00 mg/l
(17.05–201.4 mg/l), 59.35 mg/l (14.90–177.0 mg/l) and
68.18 mg/l (16.38–177.4 mg/l) for the ABX Pentra 400,
the POCT and the AU 5800, respectively.
As shown in Table 7, quality requirements were
fulfilled as TEobs remained < TEmin of 44.4% for all com-
parisons. For the majority of comparisons, TEobs was
also < TEdes of 29.6%. The only exception was the com-
parison between the POCT and ABX Pentra 400 for
CRP concentrations > 100 mg/l, where a TEobs of 31.9%
was obtained.
Establishment of reference intervals
Overall, 60 clinically healthy dogs with a median age of
2 years (range 1–9 years) were included to evaluate a
reference range for CRP as assessed with the POCT. Sex
was equally distributed with 30 male (25 intact, 5 neu-
tered) and 30 female (28 intact, 2 spayed) dogs. The
breeds were represented as follows: 11 German Shep-
herd Dogs, 9 Golden Retrievers, 9 Labrador Retrievers, 7
mixed-breed dogs, 6 Bearded Collies, 3 Great Danes, 2
Australian Kelpies, 2 Dogues de Bordeaux, 2 Rough
Collies, 2 Rhodesian Ridgebacks, 1 Bernese Mountain
Dog, and 1 Border Collie, Boxer, Bullmastiff, Cane Corso
Italiano, Hovawart, Magyar Viszla each.
Healthy dogs presented with CRP values ≤11.9 mg/l.
Discussion
The POCT was capable to detect canine CRP with an
excellent correlation with the automated immunoturbi-
dimetric test run on large bench top analyzers in both, a
university veterinary laboratory and a commercial veter-
inary laboratory, even though a proportional bias of the
assay has to be considered. Generally, quality require-
ments were fulfilled as TEobs remained < TEmin of 44.4%
and for the majority of comparisons < TEdes of 29.6%
[32]. This is in accordance with other POCTs for canine
CRP [27]. Intra- and inter-assay CVs ranging from 0 to
24% have been reported for different other POCTs at
low CRP concentrations which was generally consistent
with the results obtained here [27].
For pathologically relevant CRP concentrations of >
50 mg/l, the POCT fulfilled quality requirements, i.e
intra- and inter-assay CVs < CVopt or at least < CVdes.
Other than expected and described previously for vari-
ous assays [28, 29], highest CVs were not obtained for
samples in the lowest CRP concentration range, but at
low to medium CRP concentrations of 20–30 mg/l.
Possible explanations may be “hardware errors” due to
biochemical background reactions of the assay itself or
an impairment of the optical detection. Variations be-
tween different lots or individual test stripes of the assay
are another possible source of error. However, in case of
lot-associated variations, outliers would be observed at
several different CRP concentration ranges rather than
at one single concentration range. Alternative explana-
tions are user-dependent errors as dilution- and pipet-
ting errors. User-dependent errors, however, were
minimized as all measurements were performed by two
trained persons. Although analytical imprecision in the
concentration range between CRP concentrations of 20
and 30 mg/l is not desirable, it is considered of minor
clinical relevance as it generally does not have an impact
of the clinical decision, i.e. interpretation of the CRP re-
sults as mildly increased. However, the possibility of a
CV of 20–30% has to be taken into account when inter-
preting follow-up examinations of the patient.
The current evaluation clearly showed that a bias be-
tween the methods has to be expected even when the
Table 5 Observed interference effects of bilirubin, hemoglobin, lipid on triplicate CRP measurement with the POCT
Interferent Mean CRPcontrol
[mg/l] ± SD
Mean CRPtest
[mg/l] ± SD
Mean bias
[mg/l]
%Biasobs %Biasobs < TEdes
(29.6%)
%Biasobs < TEopt
(14.8%)
Bilirubin
800 mg/l
37.6 ± 5.6 39.8 ± 0.4 2.2 5.8 Yes Yes
Hemoglobin
4 g/l
29.5 ± 1.7 30.1 ± 4.1 0.6 2.0 Yes Yes
Soy bean emulsion
8 g/l
35.1 ± 1.4 39.1 ± 0.8 4.0 11.3 Yes Yes
Test samples (CRPtest) spiked with the interfering substances were compared to control samples (CRPcontrol) spiked with equal volume of the diluent used in the test
sample. %Biasobs (observed bias) for the interfering substance was acceptable if %Biasobs < desired total allowable error (TEdes) and excellent if %Biasobs < optimal total
allowable error (TEopt) [32]
Table 6 Results of method comparison: Intra-assay precision
Intra-assay CV median
(range) at three CRP
concentration
ranges / analyzer
Point
Reader™ V
ABX
Pentra 400
AU 5800
≥ 10 - < 50 mg/l 3.53%
(0.0–38.91%)
0.62%
(0.0–3.23%)
0.76%
(0.26–3.0%)
≥ 50 - < 100 mg/l 3.50%
(0.16–7.39%)
0.43%
(0.08–2.21%)
1.68%
(0.49–5.60%)
≥ 100 - < 200 mg/l 5.62%
(0.40–16.60%)
0,30%
(0.0–0.60%)
1.50%
(0.52–2.27%)
Intra-assay CVs for the CRP analysis obtained from duplicate measurements
performed on two automated bench top analyzers (ABX Pentra, AU 5800) and
the point-of-care analyzer
Abbreviations: CV coefficient of variation
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same test is used as it was the case for the ABX Pentra
400 and the AU 5800 bench top analyzer. The current
results show that the bias is not only caused by the dif-
ferent ability of the antibody used in the test to bind
canine CRP but also by the analyzer itself. The impact of
the analyzer on assay results has already been discussed
in the literature for the same CRP assay which is used as
reference method in the current study [27, 29].
Moreover, an impact of different lots of the Gentian
Canine CRP Immunoassay on the results cannot be
entirely ruled out.
As demonstrated here, the bias and thus also the
TEobs are highly dependent on the reference method
(i.e., the combination of assay and analyzer) used for
comparison. While %Biasobs between the POCT and the
bench top analyzer AU 5800 was at least fulfilling
%Biasmin [32], %Biasobs was slightly higher than Biasmin
in the comparison between the POCT and the other
bench top analyzer, ABX Penta 400. Other than
expected, even the comparison between both bench top
analyzers using the same assay revealed a mean %Bia-
sobs > than optimal bias %Biasopt. The results obtained
a1
a2
a3
b1
b2
b3
c1
c2
c3
Fig. 2 Results of method comparison between the POCT and two automated analyzers. The point-of-care analyzer was compared to a CRP assay run
on two automated large bench top analyzers (ABX Pentra 400, AU 5800). A1–3: Passing- Bablok regression analysis with 95% confidence interval (CI) of
CRP measurements performed with the three analyzers. A1: 95% CI of slope and intercept of the regression line were 0.74 to 0.90 and− 4.52 to 4.10,
respectively. A2: 95% CI of slope and intercept were 0.86 to 0.95 and − 2.15 to 2.25, respectively. A3: There was a 95% CI of slope and intercept of 0.85
to 0.95 and − 2.75 to 2.02, respectively. B1–3: Bland-Altman difference plot demonstrating mean %Biasobs with its 95% confidence interval and
its 1.96fold standard deviation (SD) indicative of its limits of agreement. The minimally acceptable total allowable error (TEmin) of 44.4% [32]
represents the quality limit. C1–3: Bland-Altman difference plot demonstrating the absolute bias between CRP measurements obtained with
three analyzers. For remainder of key, refer to Fig. 1b
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here, demonstrate clearly the impact of the choice of
the reference method on the results.
Unfortunately, a true gold standard is not available for
the measurement of canine CRP, which is a major limita-
tion of all method validation studies. Considering the
%Biasobs between both large bench top analyzers evalu-
ated here and using the same assay, a Biasobs of ~ 10%
between the POCT and the AU 5800 can be considered
as good while a Biasobs of ~ 20% between the POCT and
the ABX Pentra 400 may at least be considered as satis-
fying. Regarding the literature, a mean %bias ranging be-
tween ~ 10–30% is frequently reported in method
validation studies for POCT designed for canine CRP
analysis [27]. Due to the Biasobs, it can be concluded that
test- and analyzer -specific reference intervals and clin-
ical decision limits have to be established. Follow-up ex-
aminations should be therefore performed with the same
method and analyzer [27]. Bias between results obtained
with different analyzers should be also kept in mind,
when classifying the severity of CRP increase as mild,
moderate or severe. Also, CRP clinical decision limits re-
ported in literature may not be applicable for the POCT
[9]. As the POCT correlates well with the reference
method (r > 0.975) [31], the regression equation may be
used to adapt values reported by the POCT to values of
the Gentian Canine CRP Immunoassay [37], i.e. a CRP
value of 100 mg/l on the ABX Pentra 400 is consistent
with 80 mg/l on the POCT and 90 mg/l on the AU
5800, while a value of 50 mg/l is consistent with 40 mg/l
(Y = − 0.12 + 0.82 x) and 45 mg/l (Y = − 0.52 + 0.91 x),
respectively. Still, the option to use the equation of the
regression analysis has to be considered carefully and is
not recommended for general use (i.e, incorporation into
analyzers´ software) as measuring errors potentiate via
mathematical adaption and the true origin of results be-
comes non-transparent.
The linearity experiment demonstrated linearity of the
POCT up to a CRP concentration of 130 mg/l as well as
an excellent correlation between measured and calcu-
lated values. However, the slope of the regression line
was markedly below 1 also reflecting a marked propor-
tional bias.
The evaluation of the lower limit of quantification was
impaired by two facts: First, the POCT has an internal
technically predetermined “limit of quantified report”.
Low CRP concentrations < 5 mg/l are generally reported
as “< 5 mg/l” by the analyzer. Second, results of repeated
measurements of the analyzer at low CRP concentra-
tions < 30 mg/l, CVs are good to excellent in most cases,
but single “outliers” occurred resulting in a high CV
(Tables 3 and 4). Therefore, it is questionable if the
evaluation of two samples with low CRP concentration
levels above the reported limit of the analyzer is enough
to determine a lower limit of quantification. A higher
number of analyses of samples with CRP values > 5 mg/l
but < 30 mg/l would be needed to increase the validity
of the set limit. Regarding our own observations (Table 4),
the limit of 5 mg/l fixed internally in the analyzer appears
to be a good limit for reported values.
No interferences in clinically relevant ranges of up to
800 mg/l bilirubin, 4 g/l hemoglobin and 8 g/l soy bean
oil (Intralipid) could be detected. As metabolic disorders
associated with icteric, hemolytic or lipemic samples
occur frequently in patients with inflammatory diseases
[20] or emergency patients, the lack of impairment by
these circumstances is considered an advantage. In
contrast, interferences have been reported previously for
other CRP assays, although they had been considered
without clinical relevance [38].
In our study, statistical computation of an exact refer-
ence interval for healthy dogs was not possible as in the
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Fig. 3 Results of method comparison: Differences of medians and
ranges between the analyzers. Box- and - whisker diagram demonstrating
median and range of the CRP measurements obtained with the three
analyzers. The horizontal line in the boxes is consistent with the median,
the whiskers indicate the range and the box represents the 25th
-75th percentile
Table 7 Results of method comparison: Total observed error
TEobs at three CRP
concentration
ranges / analyzer
ABX Pentra
400 vs POCT
AU 5800 vs POCT ABX Pentra
400 vs AU 5800
≥ 10 - < 50 mg/l 27.3% 17.3% 10.7%
≥ 50 - < 100 mg/l 26.7% 16.7% 12.6%
≥ 100 - < 200 mg/l 31.9% 21.9% 12.2%
Total observed error (TEobs) for the CRP analysis performed on two automated
bench top analyzers (ABX Pentra 400, AU 5800) and the point-of-care analyzer
TEobs > TEdes (i.e., 29.6%) but < TEmin (i.e., 44.4%) is shown in bold letters
Abbreviations: vs versus, TEdes desirable total allowable error, TEmin minimally
acceptable total error
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majority of dogs CRP values < 5 mg/l were observed.
Still, this is not a disadvantage as very low CRP values
are not of clinical relevance in canine medicine. The
data demonstrate healthy dogs to show CRP values <
12 mg/l. This is comparable with most reported refer-
ence intervals for canine CRP established for various
immunoassays in literature [16, 18–20, 39] or our own
unpublished data for the Gentian Canine CRP Immuno-
assay on the ABX Pentra 400 with a reference interval ≤
10.8 mg/l CRP.
Nevertheless, another recent study [40] also reported a
wide range of normal CRP results (0.07–24.7 mg/l) ob-
tained in 76 healthy dogs using a human-based assay
(High linearity CRP, Randox, Crumlin, United Kingdom).
In the previous study, the clinical decision limit to differ-
entiate between healthy dogs or dogs without systemic
inflammation and dogs with several types of diseases as-
sociated with systemic inflammation was set at a CRP
concentration of 16.8 mg/l based on receiver operating
characteristic analysis. In contrast, in another study
evaluating a semiquantitative near-patient CRP assay, a
higher CRP concentration of 35 mg/l is used as a cut-off
value to discriminate “positive” and “negative” CRP sam-
ples [24]. However, given the bias even between ana-
lyzers using the same assay, potential bias as well as the
CV at this concentration level have to be considered. In
case of marked bias, a laboratory-specific cut-off value
has to be defined. Moreover, especially if a relatively high
CV is present as observed for the POCT at this concen-
tration range, a grey zone rather than a definite cut-off
value should be used which can be calculated based on
the analytical CV and biological variation, i.e. within dog
variation as described previously [41].
Limitations of the study included the fact that quality
specifications for CV, bias and TE based on biological
variation as published in the total allowable error guide-
lines of the ASVCP [42] were applied here, however, they
are judged as too stringent for method validation studies
[42] and are even stricter than quality goals in human
medicine [43]. As no adequate alternative is available for
veterinary medicine, they have been used also in previous
studies evaluating canine CRP assays [29].
Moreover, a possible prozone effect was not investi-
gated in our study, however, there is no evidence of a
prozone effect for a CRP range ≤ 360 mg/l (equaling
130 mg/l as assessed with the POCT) which covers a
large part but not the total range of possible CRP results
observed in diseased dogs [40, 44].
Conclusion
Overall, the species-specific Point Reader™ V is an easy-
to-use POCT suitable to detect canine CRP in lithium
heparin plasma samples precisely in concentrations be-
ing relevant for clinical decision making. The POCT
correlates well with an already established immunoturbi-
dimetric species-specific CRP assay run on large bench
top analyzers, however, the bias with other methods and
analyzers has to be considered. Thus, CRP results
assessed by different assays and/or different analyzers
are not directly comparable in follow-up examinations.
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